دورية أكاديمية
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
| العنوان: | Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial |
|---|---|
| المؤلفون: | Danese S., Vermeire S., D'Haens G., Panes J., Dignass A., Magro F., Nazar M., Le Bars M., Lahaye M., Ni L., Bravata I., Lavie F., Daperno M., Lukas M., Armuzzi A., Lowenberg M., Gaya D. R., Peyrin-Biroulet L., Rocca R., Lopes S., Caprioli F., Ardizzone S., Echarri Piudo A., Gionchetti P., Roblin X., Seidler U., Andersson D., Patel K., Desreumaux P., Saibeni S., From G., Fedurco M., Gregus M., Bouhnik Y., Luegering A., Cosintino R., Bunganic I., Ramos J., Aguas Peris M., Dewit O., Principi M., Wesley E., Lago P., Nancey S., Martin Arranz M. D., Hindryckx P., Orlando A., Geccherle A., Annunziata M. L., Hayee B., Balaz J., Portela F., Gilletta C., Kucharzik T., Minguez M., Gisbert J. P., Casbas A. G., Louis E., Marino M., Parkes G., Cummings F., Jharap B., Kjeldsen J., Correia L., Ministro P., Ebert M., Hertervig E., Staessen D., Dutre J., Colard A., Morrison G., Glerup H., Dahlerup J. F., Wolfhagen F., Batovsky M., Molnar M., Kadleckova B., Caldeira P., Laharie D., Hebuterne X., Bonaz B., Allez M., Fischer A., Hinojosa Del Val J. E., Ciria M. M., Herrera Justiniano J. M., Soderman C., Chandy R., Mowat C., Irving P., Fallingborg J., Matous J., Douda T., Altwegg R., Benitez J. M., Arroyo Villarino M. T., Capon J. G., Vicenc D. G., Dewint P., Almer S., Kindt S. |
| المساهمون: | S. Danese, S. Vermeire, G. D'Haen, J. Pane, A. Digna, F. Magro, M. Nazar, M. Le Bar, M. Lahaye, L. Ni, I. Bravata, F. Lavie, M. Daperno, M. Luka, A. Armuzzi, M. Lowenberg, D.R. Gaya, L. Peyrin-Biroulet, R. Rocca, S. Lope, F. Caprioli, S. Ardizzone, A. Echarri Piudo, P. Gionchetti, X. Roblin, U. Seidler, D. Andersson, K. Patel, P. Desreumaux, S. Saibeni, G. From, M. Fedurco, M. Gregu, Y. Bouhnik, A. Luegering, R. Cosintino, I. Bunganic, J. Ramo, M. Aguas Peri, O. Dewit, M. Principi, E. Wesley, P. Lago, S. Nancey, M.D. Martin Arranz, P. Hindryckx, A. Orlando, A. Geccherle, M.L. Annunziata, B. Hayee, J. Balaz, F. Portela, C. Gilletta, T. Kucharzik, M. Minguez, J.P. Gisbert, A.G. Casba, E. Loui, M. Marino, G. Parke, F. Cumming, B. Jharap, J. Kjeldsen, L. Correia, P. Ministro, M. Ebert, E. Hertervig, D. Staessen, J. Dutre, A. Colard, G. Morrison, H. Glerup, J.F. Dahlerup, F. Wolfhagen, M. Batovsky, M. Molnar, B. Kadleckova, P. Caldeira, D. Laharie, X. Hebuterne, B. Bonaz, M. Allez, A. Fischer, J.E. Hinojosa Del Val, M.M. Ciria, J.M. Herrera Justiniano, C. Soderman, R. Chandy, C. Mowat, P. Irving, J. Fallingborg, J. Matou, T. Douda, R. Altwegg, J.M. Benitez, M.T. Arroyo Villarino, J.G. Capon, D.G. Vicenc, P. Dewint, S. Almer |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2022 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | Settore MED/12 - Gastroenterologia |
| الوصف: | Background: A treat-to-target strategy, in which strictly defined treatment targets facilitate decision making in clinical practice, is advocated as an optimised management approach for some chronic disorders. The aim of the STARDUST trial was to assess whether a treat-to-target strategy with early endoscopy, regular biomarker and clinical symptom monitoring, and dose intensification for persistent inflammatory activity, was more successful in achieving endoscopic improvement at week 48 than a clinically driven maintenance strategy in patients with moderate-to-severe active Crohn's disease receiving ustekinumab. Methods: This open-label, multicentre, randomised phase 3b trial included adults with active, moderate-to-severe Crohn's disease (Crohn's Disease Activity Index [CDAI] 220–450 and Simple Endoscopic Score in Crohn's Disease [SES-CD] ≥3) for whom conventional therapy or one biologic therapy, or both, had failed. Patients received intravenous ustekinumab approximating 6 mg/kg at baseline and subcutaneous ustekinumab 90 mg at week 8. At week 16, patients with a CDAI improvement of 70 or more points from baseline were randomly assigned (1:1) to receive standard-of-care or treat-to-target maintenance treatment through week 48. Randomisation was balanced by using randomly permuted blocks and was stratified by biologic history status and baseline SES-CD score. All patients who signed informed consent, who were not screening failures, and who received at least one dose of study treatment were included in week 16 analyses. All patients included in week 16 analyses and randomly assigned to one of the maintenance treatment regimens were included in the week 48 efficacy and safety analyses (ie, on an intention-to-treat basis). Patients assigned to the treat-to-target arm received ustekinumab every 12 weeks or every 8 weeks based on SES-CD improvement from baseline and could escalate to every 4 weeks through week 48 if prespecified targets were missed. Patients assigned to the standard-of-care arm received ustekinumab ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/35120656; info:eu-repo/semantics/altIdentifier/wos/WOS:000794985000013; volume:7; issue:4; firstpage:294; lastpage:306; numberofpages:13; journal:THE LANCET. GASTROENTEROLOGY & HEPATOLOGY; http://hdl.handle.net/2434/918100Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85124886353 |
| DOI: | 10.1016/S2468-1253(21)00474-X |
| الإتاحة: | https://doi.org/10.1016/S2468-1253Test(21)00474-X http://hdl.handle.net/2434/918100Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.CBAB9FDC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S2468-1253(21)00474-X |
|---|